SYRA HEALTH CORP - CLASS A (SYRA) Fundamental Analysis & Valuation
NASDAQ:SYRA • US87168W2035
Current stock price
0.1043 USD
-0.02 (-17.94%)
At close:
0.0805 USD
-0.02 (-22.82%)
After Hours:
This SYRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SYRA Profitability Analysis
1.1 Basic Checks
- SYRA had negative earnings in the past year.
- In the past year SYRA has reported a negative cash flow from operations.
- In the past 5 years SYRA always reported negative net income.
- SYRA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -102.17%, SYRA is not doing good in the industry: 94.29% of the companies in the same industry are doing better.
- Looking at the Return On Equity, with a value of -130.59%, SYRA is doing worse than 80.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -102.17% | ||
| ROE | -130.59% | ||
| ROIC | N/A |
ROA(3y)-84.41%
ROA(5y)N/A
ROE(3y)-167.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 20.71%, SYRA is in line with its industry, outperforming 41.90% of the companies in the same industry.
- SYRA's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for SYRA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.1%
GM growth 5YN/A
2. SYRA Health Analysis
2.1 Basic Checks
- SYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for SYRA has been increased compared to 1 year ago.
- Compared to 1 year ago, SYRA has a worse debt to assets ratio.
2.2 Solvency
- SYRA has an Altman-Z score of -2.79. This is a bad value and indicates that SYRA is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -2.79, SYRA is doing worse than 85.71% of the companies in the same industry.
- A Debt/Equity ratio of 0.05 indicates that SYRA is not too dependend on debt financing.
- The Debt to Equity ratio of SYRA (0.05) is better than 78.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.79 |
ROIC/WACCN/A
WACC8.73%
2.3 Liquidity
- SYRA has a Current Ratio of 5.46. This indicates that SYRA is financially healthy and has no problem in meeting its short term obligations.
- SYRA's Current ratio of 5.46 is amongst the best of the industry. SYRA outperforms 95.24% of its industry peers.
- A Quick Ratio of 5.46 indicates that SYRA has no problem at all paying its short term obligations.
- SYRA's Quick ratio of 5.46 is amongst the best of the industry. SYRA outperforms 95.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.46 | ||
| Quick Ratio | 5.46 |
3. SYRA Growth Analysis
3.1 Past
- The earnings per share for SYRA have decreased by -8.98% in the last year.
- The Revenue has grown by 44.67% in the past year. This is a very strong growth!
- Measured over the past years, SYRA shows a very strong growth in Revenue. The Revenue has been growing by 78.22% on average per year.
EPS 1Y (TTM)-8.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
Revenue 1Y (TTM)44.67%
Revenue growth 3Y78.22%
Revenue growth 5YN/A
Sales Q2Q%13.63%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. SYRA Valuation Analysis
4.1 Price/Earnings Ratio
- SYRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. SYRA Dividend Analysis
5.1 Amount
- SYRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SYRA Fundamentals: All Metrics, Ratios and Statistics
0.1043
-0.02 (-17.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-11 2025-03-11/bmo
Earnings (Next)05-07 2025-05-07
Inst Owners6.21%
Inst Owner Change0%
Ins Owners0.62%
Ins Owner Change0%
Market Cap1.18M
Revenue(TTM)7.98M
Net Income(TTM)-3.76M
AnalystsN/A
Price Target1.84 (1664.14%)
Short Float %0.68%
Short Ratio0.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.36%
Min Revenue beat(2)-2.21%
Max Revenue beat(2)10.93%
Revenue beat(4)3
Avg Revenue beat(4)9.8%
Min Revenue beat(4)-2.21%
Max Revenue beat(4)22.54%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.15 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.41 | ||
| P/tB | 0.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.54
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.71
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -102.17% | ||
| ROE | -130.59% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.71% | ||
| FCFM | N/A |
ROA(3y)-84.41%
ROA(5y)N/A
ROE(3y)-167.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.1%
GM growth 5YN/A
F-Score4
Asset Turnover2.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 17.7% | ||
| Cap/Sales | 0.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.46 | ||
| Quick Ratio | 5.46 | ||
| Altman-Z | -2.79 |
F-Score4
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)287.72%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.86%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)44.67%
Revenue growth 3Y78.22%
Revenue growth 5YN/A
Sales Q2Q%13.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.27%
OCF growth 3YN/A
OCF growth 5YN/A
SYRA HEALTH CORP - CLASS A / SYRA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of SYRA HEALTH CORP - CLASS A (SYRA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to SYRA.
Can you provide the valuation status for SYRA HEALTH CORP - CLASS A?
ChartMill assigns a valuation rating of 0 / 10 to SYRA HEALTH CORP - CLASS A (SYRA). This can be considered as Overvalued.
Can you provide the profitability details for SYRA HEALTH CORP - CLASS A?
SYRA HEALTH CORP - CLASS A (SYRA) has a profitability rating of 0 / 10.
What is the financial health of SYRA HEALTH CORP - CLASS A (SYRA) stock?
The financial health rating of SYRA HEALTH CORP - CLASS A (SYRA) is 4 / 10.